Files and links (1)
Published (Version of Record)CC BY V4.0, Open Access
Journal article
In vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, and Strains With Linezolid Resistance Genes From China
Frontiers in microbiology, Vol.12, 729900
08/2021
PMCID: PMC8417360
PMID: 34489919
Abstract
Contezolid is a novel oxazolidinone, which exhibits potent activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and penicillin-resistant Streptococcus pneumoniae (PRSP). In this study, the in vitro activity of contezolid was compared with linezolid (LZD), tigecycline (TGC), teicoplanin (TEC), vancomycin (VA), daptomycin (DAP), and florfenicol (FFC) against MRSA and VRE strains isolated from China. Contezolid revealed considerable activity against MRSA and VRE isolates with MIC90 values of 0.5 and 1.0 μg/mL, respectively. For VRE strains with different resistance genotypes, including vanA- and vanM-type strains, contezolid did not exhibit significantly differential antibacterial activity. Furthermore, the antimicrobial activity of contezolid is similar to or slightly better than that of linezolid against MRSA and VRE strains. Subsequently, the activity of contezolid was tested against strains carrying linezolid resistance genes, including Staphylococcus capitis carrying cfr gene and Enterococcus faecalis carrying optrA gene. The results showed that contezolid exhibited similar antimicrobial efficacy to linezolid against strains with linezolid resistance genes. In general, contezolid may have potential benefits to treat the infections caused by MRSA and VRE pathogens.
Details
- Title
- In vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, and Strains With Linezolid Resistance Genes From China
- Authors/Creators
- Siheng Wang - , , , , , , , , , , , ,Chang Cai - , , , , , , , , , , , ,Yingbo Shen - , , , , , , , , , , , ,Chengtao Sun - , , , , , , , , , , , ,Qingxin Shi - , , , , , , , , , , , ,Ningjun Wu - , , , , , , , , , , , ,Shufang Zheng - , , , , , , , , , , , ,Jiao Qian - , , , , , , , , , , , ,Rong Zhang - , , , , , , , , , , , ,Hongwei Zhou - , , , , , , , , , , , ,
- Publication Details
- Frontiers in microbiology, Vol.12, 729900
- Publisher
- Frontiers Media S.A
- Identifiers
- 991005578651507891
- Copyright
- © 2021 Wang, Cai, Shen, Sun, Shi, Wu, Zheng, Qian, Zhang and Zhou.
- Murdoch Affiliation
- Centre for Biosecurity and One Health
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Metrics
99 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.23 Antibiotics & Antimicrobials
- 1.23.173 MRSA and VRE
- Web Of Science research areas
- Microbiology
- ESI research areas
- Microbiology